Issue 9 2021

Acquisition International - Issue 9 2021 25 24 Acquisition International - Issue 9 2021 Websit e: deybllp.co m 17 Jul21338 Company: Darger Errante Yavitz & Blau LLP Contact: Craig Blau Website: deybllp.com Legally Excellent, Client First arger Errante Yavitz & Blau LLP – or DEYB – is a company two-thirds owned by women, and one that has been accredited by Forbes, New York Magazine, U.S. News, World Report, Super Lawyers magazine, and more, earning it the title of the ‘Best Boutique Law Litigation Firm’ in the USA. DEYB, first and foremost, represents Fortune 500 companies in all sorts of legal entanglements where they require representation, serving clients across all manner of industries. These include automotive, construction, electrical, energy, consumption, pharmaceutical, and safety equipment provision, and its staff each have the wide portfolios and expansive knowledge of legislation past and present to be able to offer comprehensive and well-thought-out legal solutions. In addition, its attorneys have a national pedigree when it comes to their expertise. With the knowledge gained throughout their personal careers, and the myriad wins they have achieved throughout their time at DEYB, they have accumulated a national reputation for success and reliability in all manner of highly complex cases. Truly, nothing is too complicated or difficult for the team at DEYB; each of them are always up for the next challenge and will approach it with empathy and hard work, managing mass tort claims, product liability cases, and business disputes for any number of professionals from large companies to small businesses and individuals. Fundamentally, it has spent years working hard to achieve this hard- won expertise. Having funnelled significant effort into building a team around it who could help its clients at every turn, come what may, it now boasts legal skills at the top of its industry. Competing even with the top international law firms in this manner, it enjoys repute amongst the loudest voices in its industry, bringing ‘big firm’ experience paired with personalised, empathic service, at cost effective rates. In essence, this is what has allowed it to become the ‘go to’ for so many different companies and individuals – especially in cases of asbestos defence litigation – and in New York, it serves the city as its New York City Defence Liaison Counsel. Here, it is behind the coordination and organisation of many different legal cases and concerns, handling litigations for dozens of law firms and hundreds of companies in the region with sophistication and a perseverance that each of its clients have lauded as exemplary. DEYB also takes diversity and inclusion incredibly seriously. By incorporating such things as intrinsic values upon which the rest of its firm has been built, DEYB creates a healthy and productive D Being the ‘Best Boutique Litigation Law Firm’ in 2021 for the USA has come with significant boosts to pedigree and repute for Darger Errante Yavitz & Blau LLP, both of which it has been building up since its inception. Critically, this law firm is one of inclusion and determination, working hard to provide its clients with the legal representation they need, and the people behind the legislation that they can truly connect with. environment that is safe and accepting for all of its employees and for its clients, knowing that in order to have a comprehensive law team, one must incorporate all perspectives. Essentially, the wide range of backgrounds and personalities in the team means that DEYB’s clients will always find someone they click with and who possesses the knowledge that will be the most helpful to them, believing that the individual is an intrinsic and pivotal part of law service. Additionally, being minority-owned, DEYB is staunchly determined to ensure this only improves as it moves towards the future, taking its clients with it into the new era of law and litigation. The Answer to Antibiotic Immunity BioPlx Inc, having earned the ‘Award for Innovation: Microbiomics Development’ in 2021, has been working hard to demonstrate the clinical safety and effectiveness of non-antibiotic products. With more people than ever not responding to antibiotic treatment due to the drugs being overprescribed, BioPlx is lending the medical industry a solution, with the results of safe and effective clinical trials, pioneering new microbiomic product patents, and an extended clinical platform of IP filings across multiple dimensions. eing both advanced and innovative, BioPlx Inc has made a name for itself with the provision of Microbiomics; essentially, non-antibiotic control methods for the handling of infectious disease. Fundamentally, its work includes multiple-drug resistant ‘super bug’ busting products that can take over from antibiotics when those products no longer function to stop an infection in its tracks, allowing the medical world to respond to mutations in the DNA of those diseases. BioPlx employs a wide range of industry leading minds in order to do so, and by use of its targeted microbiological agents, it creates unique formulae and brilliant therapeutic solutions that restore a microbiome to its original function, making it a first line of defence against disease. Additionally, it is focused on helping hospitals and communities control the spread of infectious disease. With an especial concentration of its services working on community acquired dermal diseases such as MRSA, v-MSSA, and more, its emphasis is on preventing recurrence B Jul21467 and stopping reinfection, allowing regions to wrest control back in the face of what threatens its people. Furthermore, BioPlx ensures that all of its work is thoroughly tested before it leaves the lab. Having collected both clinical and pre-clinical data about its products prior to release, it is always ready and willing to show clients and stakeholders the proof behind the effectiveness of what they are looking to receive from it – in terms of its results and in terms of its safety for end users. Having filed several patents that protect its unique products and ways of working, its platform is thoroughly its own creation, and its targeted orphan drug and IND designations are slated to soon also be patented, having established a number of private equity and angel backers within its industry. This, in essence, means that BioPlx is always ready to hit the market when it releases new products, and that its clients can trust it will only release what it is truly proud to serve. Regarding its platform in particular, this provision seeks to combine advances in microbiome ecology with novel genetic methods, resulting in a unique, safe, sophisticated space to develop functional characteristics for many different microbiome-associated organisms. BioPlx’s work is determined to change the world of medical product development for the future by showing it how keeping a finger on the pulse of adaptation, change, and alteration is a good thing. With the overuse of antibiotics causing difficulties in the population wherein the drugs that previously worked no longer have the desired effect, BioPlx is there to provide the solution that the market is hankering for, especially when the pathogen returns in a patient after a treatment method has been explored without warning. This has been especially helpful for hospitals dealing with MRSA, as BioPlx has developed the first interventional microbiomic treatment for the disease, saving billions of dollars for the institutes trying to treat this disease as soon as it emerges in a patient. Having gained renown for services like this, it will be using such things as a springboard as it moves towards the bright future that is surely ahead, becoming more and more the medical industry’s backbone as it develops and demonstrates the effectiveness of a new class of solution. Company: BioPlx Inc. Contact: Ravi Starzl Website: bioplx.com